Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2022
Lead Product(s) : ATI-2173,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University of Cape Town | University of Liverpool | Imperial College London | MRC/UVRI Uganda Research Unit | Karolinska Institutet | King's College London | London School of Hygiene & Tropical Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2019
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University of Cape Town | University of Liverpool | Imperial College London | MRC/UVRI Uganda Research Unit | Karolinska Institutet | King's College London | London School of Hygiene & Tropical Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : United States Agency for International Development | Agility Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, PK, and PD Study of IVRs Releasing TFV and LNG
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2017
Lead Product(s) : Tenofovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : United States Agency for International Development | Agility Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Eastern Virginia Medical School | University of North Carolina | Agility Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Exploratory Pharmacodynamic Study of Tenofovir-Based Products
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 30, 2016
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Eastern Virginia Medical School | University of North Carolina | Agility Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Fundació Clínic per a la Recerca Biomèdica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2015
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Fundació Clínic per a la Recerca Biomèdica
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2015
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2014
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Merck & Co | Ministry of Health, Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2014
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Merck & Co | Ministry of Health, Brazil
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Hassle Free Clinic | Maple Leaf Research | Toronto Metropolitan University | AIDS Committee of Toronto | Canadian AIDS Treatment Information Exchange | Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2014
Lead Product(s) : Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Hassle Free Clinic | Maple Leaf Research | Toronto Metropolitan University | AIDS Committee of Toronto | Canadian AIDS Treatment Information Exchange | Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
